A.J. Jakubowiak, W. Bensinger, D. Siegel et.al. Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma Fllowing 1 to 3 Prior Therapies: Interim Results. ASH 2009, poster presentation.

S. Lonial, R. Vij, J-L Harousseau, et. al. Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results. ASH 2009, oral presentation.

A.J. Jakubowiak, D. Siegel, W. Bensinger, et. al. Phase I Study of Elotuzumab in Combination with Bortezomib +/- Dexamethasone in MM Patients with 1-3 Prior Therapies: Interim Results, International Myeloma Workshop 2009, oral presentation.

Sagar Lonial1, Ravi Vij2, Christopher Westland3, Anil Singhal3, and Sundar Jagannath4, Phase 1b Study of Elotuzumab (HuLuc63) in Combination with Lenalidomide/dexamethasone in Relapsed Multiple Myeloma: Interim Results, International Myeloma Workshop 2009, poster presentation.

J. Zonder, S. Singhal, W. Bensinger, A. Mohrbacher, M. Hussein et al. Phase 1, Dose Escalation Study of Elotuzumab (HuLuc63) in Patients with Relapsed/Refractory Multiple Myeloma: Interim Results. ASH 2008, poster presentation.

B. Balasa, M. Huseni, J. Cherukuri, R. Steinle, A. Nanisetti, et al. Elotuzumab (HuLuc63) Activates CD56dim Natural Killer Cells and Monocytes Resulting in Secretion of IP-10 and MCP-1 Chemokines. ASH 2008, oral presentation.

T. K. Garg, S. Szmania, J. Shi, K. Stone, A. Moreno-Bost, P. Malbrough, D. Campana, B. Barlogie, D. E.H. Afar, F. van Rhee. Ex vivo activated natural killer (NK) cells from myeloma patients kill autologous myeloma and killing is enhanced by elotuzumab. ASH 2008 poster presentation.

E. D. Hsi, R. Steinie, B. Balasa, A. Rice, Y-H. Ko, and D. E.H Afar. CS1 is expressed in Nasal type NK/T cell lymphomas: Implications for targeted therapy with Elotuzumab (HuLuc63). ASH 2008 poster presentation.

Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatmant of multiple myeloma. Clin Cancer Re. 2008;14(9):2775-2784.

Tai Y-T, Dillon M, Song W, et al. Anti-CS1 hummanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329-1337.

W Bensinger, J Zonder, S Singhal, A Mohrbacher, R Dean, F van Rhee, S Al Homsi, N Munshi, H Ding, E Conner, L Jesaitis,  M Hussein. Phase 1, Open-Label, Dose Escalation Study of HuLuc63 in Patients with Advanced Multiple Myeloma. ASH 2007, poster presentation.

YT Tai, AG Rice, M Leiba, XF Li, P Burger, W Song, R Prabhala, M Dillon, L Jesaitis, I Caras, E Toolan, W Xie, T Hideshima, N Raje, P Richardson, NC Munshi, A Nagler, H Avet-Loiseau, C Mathiot, DEH Afar, KC Anderson. Low levels of circulating CS1, a newly identified multiple myeloma antigen for a novel humanized monoclonal antibody (HuLuc63), is detected in MM patient sera and correlates with active disease. ASH 2007, poster presentation.

YT Tai, W Song, XF Li, P Burger, R Schlossman, A Rice, A van Abbema, P Richardson, NC Munshi, D Afar, KC Anderson. Killing of drug-sensitive and resistant myeloma cells and disruption of their bone marrow stromal interaction by HuLuc63, a novel humanized anti-CS1 monoclonal antibody. ASH 2006, poster presentation.

A Rice, M Dillon, S Chen, A van Abbema, T Emek, D Chao, DEH Afar. HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-tumor Activity in Pre-clinical Models of Myeloma. ASH 2007, poster presentation.

D Afar, S Szmania, M Dillon, A Rice, A van Abbema, T Emek, D Chao, J Shaughnessy, B Barlogie, F van Rhee. Anti-Myeloma activity of HuLuc63 alone and in combination with bortezomib. 2007 International Myeloma Workshop, poster presentation.

S Szmania, B Balasa, P Malaviarachchi, F Zhan, Y Huang, A Draksharapu, V Vexler, J Shaughnessy, B
Barlogie, G Tricot, D Afar, F van Rhee. CS1 is expressed on myeloma cells from early stage, late stage,  and drug-treated multiple myeloma patients, and is selectively targeted by the HuLuc63 antibody.  ASH 2006, oral presentation.

ED Hsi, R Steinle, B Balasa, A Draksharapu, B Shum, M Huseni, D Powers, A Rice, G Liu, A Nanisetti, M Williams, V Vexler, M Hussein, D Afar. Expression of CS-1 (SLAMF7) in Benign And Neoplastic Plasma Cells: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma. ASH 2006, poster presentation.

A Rice, M Dillon, A van Abbema, L Jesaitis, M Wong, S Lawson, G Liu, Y Zhang, D Powers, S Rhodes, I Caras, D Law, D Afar. Eradication of tumors in pre-clinical models of mulitiple myeloma by anti-CS1 monoclonal antibody HuLuc63. ASH 2006, poster presentation.